- Home
- PLBC vs RIGL Comparison
PLBC vs RIGL Comparison
Compare PLBC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBC | RIGL |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 537.6M |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PLBC | RIGL |
|---|---|---|
| Price | $45.28 | $37.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $55.00 | $43.20 |
| AVG Volume (30 Days) | 13.2K | ★ 586.0K |
| Earning Date | 01-16-2026 | 03-03-2026 |
| Dividend Yield | ★ 2.65% | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | 4.23 | ★ 6.20 |
| Revenue | $89,868,000.00 | ★ $282,076,000.00 |
| Revenue This Year | $21.11 | $65.53 |
| Revenue Next Year | $16.11 | $0.22 |
| P/E Ratio | $10.71 | ★ $6.31 |
| Revenue Growth | 12.51 | ★ 79.13 |
| 52 Week Low | $38.71 | $15.50 |
| 52 Week High | $49.47 | $52.24 |
Technical Indicators
Market Signals| Indicator | PLBC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.16 | 40.08 |
| Support Level | $44.45 | $37.00 |
| Resistance Level | $45.02 | $49.10 |
| Average True Range (ATR) | 0.88 | 2.64 |
| MACD | -0.07 | -0.69 |
| Stochastic Oscillator | 68.47 | 7.85 |
Price Performance
Historical ComparisonAbout PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.